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P. De Rango*
Division of Vascular and Endovascular Surgery, Hospital S. M. Misericordia, Perugia, ItalyData from VASCUNET, a large registry of vascular practice col-
lecting data from nine European countries and Australia, published
in this issue of EJVES, alerted on the large variability in indications
and treatment of carotid stenosis in national practice of the real
world.1 According to data from 48,185 carotid endarterectomies
(CEA) and 4602 carotid stenting (CAS) recorded over a 5-year
period (2005e2010) and stratiﬁed by participating countries, the
proportion of CAS varied from 0.1% to 17.4% of the overall national
procedures in each country. Furthermore, although the indication
for CEA in the overall registry was mainly symptomatic carotid
stenosis (60.1%), the proportion signiﬁcantly varied from 100% to
31.4% (p < 0.001). In addition, there were markedly differences in
application of CEA by gender (proportion of women from 39% to
28.8%; p < 0.001), age (proportion of >75 y old patients from 45.6%
to 18.7%; p < 0.001) and in admission mode (emergency of repairs
from 2.1% to 24.6%, p < 0.001). The large inconsistency in regular
practice with carotid surgery among different countries shown by
VASCUNET might be overestimated due to reporting bias related to
the registry source of data. Registries are not as reliable as clinical
trials and may be likely affected by inaccuracy and missing infor-
mation. However, even with limitations, registry data can provide
a picture of current practice in the real world.
Variability in carotid practice found in the VASCUNET registry is
improbably related to difference in prevalence and characteristics
of patients with the disease since data were recorded through the
same geographic area and ethnicity groups and only in part can
reﬂect lack of adherence to established carotid guidelines since
most of the procedures in each country were performed according
to European recommendations (from 70.3% to 100%; overall
adherence 92.3%).1 More likely, the lack of a uniformed practice
may be related to weakness in the current evidence in manage-
ment of carotid disease. Despite multiple randomized clinical trials
(RCT) and multiple guidelines published, carotid stenosis is still
a largely unknown disease with many controversial issues. There
are only few strong certainties (CEA is effective for recurrent stroke
prevention in symptomatic severe carotid stenosis) but more
unclear features in carotid related stroke for which the evidence of
beneﬁt from an intervention is weak and the strength or recom-
mendations for management of carotid stenosis is low, as outlined
in the following points:DOI of original article: 10.1016/j.ejvs.2012.04.013.
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doi:10.1016/j.ejvs.2012.04.026 One controversial ﬁeld is the use of interventional therapy for
asymptomatic disease: although two RCTs observed that CEA
conferred a signiﬁcant beneﬁt over medical therapy alone, the
beneﬁt was small, never balanced with current medical
therapy advancements, and failed to achieve the level of
multidisciplinary consensus accorded to RCTs for symptomatic
carotid stenosis because the overall risk of stroke for patients
with asymptomatic carotid disease is low.
 Regarding symptomatic carotid disease, there is increasing
evidence suggesting the greatest beneﬁt from surgery if the
operation is performed soon after onset of symptoms, but there
is no level-I evidence and none of the published studies clearly
demonstrated the beneﬁt for the patients in balancing opera-
tive early risks in iperacute stroke/TIA patients and the efﬁcacy
in late stroke prevention.
 Furthermore, carotid guidelines state that surgery may confer
beneﬁt also in old patients and women; however, the proofs of
efﬁcacy in these age and sex settings are controversial and the
beneﬁt is lower than that achieved in young male patients.
 Finally, what about the indication for CAS, the most debated
procedure in the history of vascular surgery, recently insti-
gating guidelines battle amongst American cardiovascular
societies? The current American Heart Association (AHA)
guidelines state that “carotid artery stenting is an alternative to
carotid endarterectomy in symptomatic average and low-risk
patients” while the Society for Vascular Surgery (SVS) guide-
lines recommend that “CAS should be reserved for symptom-
atic patients with stenosis of 50%e99% at high risk for CEA for
anatomic or medical reasons and is not recommended for
asymptomatic patients at this time”. There is still confounded
and limited evidence on the safety and long-term efﬁcacy of
CAS that can difﬁculty support the widespread use of the
procedure especially for asymptomatic carotid stenosis
currently overcoming 90% of the carotid interventions in many
(especially US) countries.
Opposite of CAS, CEA is today recognized a safe procedure as
conﬁrmed by the VASCUNET registry data showing very low peri-
procedural risks with narrow ranges by country: 2.3% in symp-
tomatic (from 0.9% to 3.8%) and 0.9% in asymptomatic (from 0.5% to
2.7%).1 However, the main goal of any carotid procedure is the
prevention of stroke. As a preventive strategy, the lack of compli-
cation must not translate in acquisition of beneﬁt for the patient if
there is no scientiﬁc proof of this efﬁcacy point.ed by Elsevier Ltd. All rights reserved.
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ence to guidelines and quality control methods for practice are
essential to uniform the management of carotid stenosis among
different countries. Nevertheless, despite carotid stenosis has been
one of the most studied conditions, we should be aware that the
“gray area” is still large and this likely reﬂects current variability in
clinical national practice. More research to help identifying the
higher beneﬁt strategy for patients in many yet un-clariﬁed carotid
settings would allow more uniform consensus and overcome this
variability. In the meantime, the best practice should be to unani-
mously apply carotid revascularization prevalently to those settingswith higher and clearer evidence of beneﬁt (i.e. symptomatic
severe carotid stenosis) and decrease the rate of application for
those where the proof of efﬁcacy are weak (e.g. asymptomatic,
women, elderly, CAS).Reference
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